Highlight Therapeutics reports positive Phase 2b results for BO-112 in high‑risk head and neck basal cell carcinoma
Highlight Therapeutics announced that its Phase 2b study of BO-112 met the primary endpoint of visual and pathological response at week 24 in patients with localized high‑risk head and neck basal cell carcinoma. The trial also demonstrated a favorable safety profile with no serious adverse events reported.
The data were presented at the European Academy of Dermatology and Venereology (EADV) congress in Vienna, underscoring the potential of BO-112 as a non‑surgical treatment option for this patient group.
The company plans to move BO-112 into late‑stage development, aiming to provide an alternative for patients with high‑risk basal cell carcinoma where current treatment needs are greatest.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that